Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Zymeworks ( (ZYME) ) is now available.
Zymeworks announced the presentation of preliminary data from its Phase 1 trial of ZW191, an antibody-drug conjugate targeting folate receptor-⍺, at an international cancer conference. The data highlights ZW191’s potential in treating advanced solid tumors, including ovarian and lung cancers, and supports the company’s broader ADC portfolio. This development underscores Zymeworks’ commitment to advancing differentiated therapies for challenging cancers, potentially impacting its market positioning and offering new treatment options for patients.
The most recent analyst rating on (ZYME) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
Zymeworks’ overall score is driven by strong earnings call insights, including revenue growth and regulatory successes. However, financial performance and valuation concerns, particularly profitability and cash flow issues, weigh down the score. Technical analysis provides a positive outlook, but the negative P/E ratio and lack of dividends are significant detractors.
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. is a global clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company aims to improve treatments for difficult-to-treat diseases such as cancer, inflammation, and autoimmune diseases. Zymeworks leverages its proprietary therapeutic platforms to develop highly differentiated antibody-based therapeutic candidates. Notably, the company has developed zanidatamab, a HER2-targeted bispecific antibody, which has received various approvals for treating HER2-positive biliary tract cancer.
Average Trading Volume: 527,386
Technical Sentiment Signal: Buy
Current Market Cap: $1.37B
Find detailed analytics on ZYME stock on TipRanks’ Stock Analysis page.